MedPharm announced a multi-million dollar investment by Ampersand Capital Partners.
Since its founding almost 20 years ago, MedPharm has established itself as a trusted developer of topical and transdermal products for the pharmaceutical drug development communities worldwide. The company’s services currently encompass formulation development, performance testing and clinical trials manufacturing at its facilities in Guildford, UK and Durham, NC, US.
MedPharm’s founders, Dr. Andrew Muddle and Prof. Marc Brown, will remain with the company to work with its growing executive team to expand MedPharm’s service offering in topical and transdermal pharmaceutical development and manufacturing, as well as increase international CDMO market coverage while maintaining the company’s scientific principles and philosophy.
“We are excited to partner with Ampersand to diversify MedPharm’s service offering and regional coverage. We look forward to growing the business together for the benefit of our customers,” Dr. Andrew Muddle, co-Founder and CEO of MedPharm, said.
The actual sum of the investment was not disclosed